Atram

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atram

Property Description
Active ingredient Carvedilol
Form Tablets (Film-coated)
Pharmacological class Beta-adrenergic blocker with Alpha-1 blocker properties
General purpose Manages circulatory performance and reduces blood pressure
Origin Synthetic small molecule

What is Atram and What is its Core Ingredient?

Atram is a prescription-only medicine whose sole active ingredient is Carvedilol, a synthetic small molecule used to influence the cardiovascular system. The preparation is administered via the oral route and is commonly supplied as tablets or film-coated tablets, defining its physical dosage form. The medication is recognized as a single active ingredient product, meaning its full therapeutic profile is derived exclusively from the chemical properties of Carvedilol.

The composition and precise manufacturing of this preparation ensure a standardized and stable delivery of the active substance. The rigorous pharmacological standards applied to drugs of this nature underscore the complexity of agents designed for systemic cardiovascular action.

Pharmacological Class and Dual Action Principle

Atram belongs to the distinct pharmacological class of adrenergic blockers, functioning uniquely as both a nonselective beta-adrenergic blocker and an alpha-1 adrenergic blocker. This dual action principle is central to its therapeutic application. The efficacy of Carvedilol is recognized in managing sustained cardiovascular challenges.

The nonselective beta-blockade regulates the force and speed of the heartbeat, reducing the workload on the heart muscle. Simultaneously, the alpha-1 blockade promotes peripheral vasodilating effects, assisting in the relaxation and widening of blood vessels. The medicine's general purpose is to combine these actions to decrease the overall resistance against which the heart pumps blood, thereby promoting more efficient circulatory performance in patients with conditions like high blood pressure.

Carvedilol: The Nature of the Drug Substance

The core drug substance, Carvedilol, is manufactured as a racemic mixture, containing both the R(+)-carvedilol and S(-)-carvedilol forms, which collectively contribute to the drug’s intended effect. This dual-isomer composition is a distinctive feature of the molecule, separating its action profile from single-isomer or selective-only beta-blockers. The tablets consist of this active substance combined with various solid pharmaceutical excipients necessary for bulk, stability, and proper absorption, ensuring accurate delivery via the oral route.

Regulatory References

  1. NIH MedlinePlus on Carvedilol

What side effects are possible with Atram?

Official Adverse Reactions and Safety Profile

The information regarding possible side effects and safety restrictions for Atram (Carvedilol) is based strictly on data documented by government regulatory bodies, such as the U.S. FDA and European national medicines agencies.

Adverse reactions are classified by how often they occur:

Frequency Examples of Adverse Reactions (by Regulatory Classification)
Very Common (≥ 10%) Fatigue, Asthenia (weakness), Dizziness, Hypotension (low blood pressure).
Common (1% to < 10%) Headache, Bradycardia (slow heart rate), Orthostatic Hypotension (low blood pressure upon standing), Syncope (fainting), Edema, Hyperglycemia, Nausea, Diarrhea.
Uncommon (0.1% to < 1%) Sleep disorders, Paresthesia (tingling/numbness).

Serious adverse reactions documented in regulatory warnings include the risk of Severe Cutaneous Adverse Reactions (SCARs), such as Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS). Abrupt discontinuation is strongly advised against, particularly in patients with Coronary Artery Disease, due to the risk of a severe exacerbation of angina or myocardial infarction.

Safety-Related Restrictions and Considerations

The medication is contraindicated (should not be used) in patients with specific pre-existing conditions as noted in official labeling:

  • Cardiac Conditions: Including severe bradycardia (unless a permanent pacemaker is present), second- or third-degree AV block, and sick sinus syndrome.
  • Severe Hepatic Impairment (severe liver function issues).
  • Bronchospastic Conditions (such as bronchial asthma).

Time-Related Patterns: The risk for low blood pressure and syncope (fainting) is documented as being highest during the first 30 days of dosing (the titration period). Furthermore, the medicine may mask symptoms of acute hypoglycemia in patients with diabetes or mask clinical features of thyrotoxicosis.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Atram (Carvedilol) may present with documented, severe exaggerations of its pharmacological effects. The official regulatory labeling identifies specific clinical manifestations and severe outcomes that require immediate medical attention.

Documented Overdose Manifestations

Overdose presentations include profound hypotension (severely low blood pressure), severe bradycardia (abnormally slow heart rate), and worsening cardiac insufficiency. Other formally described signs may include dizziness, vomiting, seizures, and loss of consciousness. Life-threatening outcomes documented in regulatory sources include cardiogenic shock and cardiac arrest.

Emergency Actions

The most important action mandated by regulatory authorities is to seek immediate medical attention for any suspected overdose. Patients are instructed to call a doctor or Poison Control Center right away. Immediate contact with emergency services is required if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Treatment focuses on supportive and symptomatic management, which, as officially described, includes placing the patient in a supine position and may involve the administration of agents such as Atropine, Glucagon, and Sympathomimetics to stabilize cardiovascular function. Hospitalization and continuous monitoring of vital signs are typically necessary.

Therapeutic Uses of Atram

Atram (Carvedilol) is applied across several major cardiovascular domains to provide supportive relief and assist in long-term support. The medication is commonly used to help with the management of systemic hypertension (high blood pressure), chronic heart failure, and for stabilization following a myocardial infarction (heart attack).

In these chronic conditions, Atram is relevant for easing symptom clusters that interfere with daily functioning, such as persistent fatigue and unusual tiredness related to poor circulation. This focus on long-term comfort is relevant. The treatment is generally relevant for easing the symptoms related to systemic imbalance, which contributes to easing the overall symptom load over time.

By supporting heart function and maintaining controlled blood pressure, Atram assists with maintaining functional stability where the patient experiences heightened systemic burden. The use is relevant for easing further functional decline and is commonly used to help with easing symptoms of chronic stable angina (chest discomfort).


Quick Fact: Relief for Impaired Functional Tolerance Atram may support improved heart function, which may assist with reducing functional limitations like shortness of breath and fatigue in patients with chronic cardiovascular stress.

Regulatory References

  1. U.S. Food and Drug Administration (FDA) Prescribing Information

Eligibility and Restrictions for Use

Who can and cannot use Atram (Carvedilol)?

The eligibility profile for Atram is defined by government regulatory agencies through specific clinical, physiological, and age-related rules, strictly outlining which populations are permitted or prohibited from using the medicine.

Eligibility Status Officially Documented Restriction/Rule
Absolute Contraindications Contraindication is mandated for patients with severe hepatic impairment, bronchial asthma or related bronchospastic conditions, and for those in cardiogenic shock or decompensated heart failure requiring IV inotropic therapy.
Use is also prohibited in patients with specific electrical disturbances, including Second- or third-degree AV block and severe bradycardia (unless a permanent pacemaker is in place).
Age-Related Status Atram is not approved for use in children under 18 years of age because safety and efficacy have not been established in the pediatric population.
Older adults may be more susceptible to effects and require careful monitoring, as indicated in regulatory documentation.
Special Physiological Status Pregnancy: Use is permitted only if potential benefit justifies the potential risk to the fetus, as determined by official risk assessments. Lactation: Use is not recommended for breastfeeding mothers.
Conditional Use Patients with pre-existing conditions like diabetes or peripheral vascular disease require explicit caution and monitoring when using Atram, as specified in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Atram (Carvedilol) has officially documented interaction patterns based on its metabolism and its cardiovascular effects. These interactions are categorized by how they alter drug exposure or result in additive pharmacological effects.


Pharmacokinetic Interactions

Interactions that alter plasma concentrations are largely due to Cytochrome P450 (CYP) enzyme modulation. Co-administration with CYP2D6 inhibitors (e.g., Fluoxetine, Quinidine) may increase Carvedilol plasma levels. Conversely, the potent enzyme inducer Rifampin significantly decreases Carvedilol systemic exposure (AUC/Cmax). Separately, Carvedilol can increase trough concentrations of Cyclosporine by inhibiting P-glycoprotein-mediated transport.

Pharmacodynamic Interactions

These additive effects involve agents that influence heart rate or blood pressure.

Interacting Substance/Class Official Interaction Pattern
Digitalis Glycosides (Digoxin) Increased risk of bradycardia due to additive slowing of AV conduction.
Calcium Channel Blockers (Verapamil, Diltiazem) Risk of severe hypotension and conduction disturbances (AV block).
Insulin & Oral Hypoglycemics May enhance the action of these agents and mask signs of acute hypoglycemia.

Timing and Population Restrictions

Carvedilol must be taken with food to slow absorption and reduce the incidence of orthostatic effects. The use of Carvedilol is contraindicated in patients with severe hepatic impairment due to the resulting significantly increased drug plasma concentrations.

Mechanism of Action

Atram functions primarily as a selective antagonist at the GABA A receptor complex, specifically targeting the benzodiazepine binding site. Following systemic absorption, Atram crosses the blood-brain barrier and binds allosterically to a specific domain on the GABA A receptor, which is an integral ligand-gated chloride ion channel. This binding induces a conformational change in the receptor structure. This modification increases the affinity of the receptor for its primary endogenous neurotransmitter, gamma-aminobutyric acid (GABA), without acting as an agonist itself. Increased GABA binding frequency enhances the opening of the central chloride channel. The subsequent influx of negatively charged chloride ions causes hyperpolarization of the neuronal cell membrane, which increases the threshold for action potential generation. This overall cellular consequence results in a reduction of neuronal excitability and firing rate within key areas of the central nervous system, mediating its physiological effects.

Dosage and Administration Information

How Atram is Used: Administration Guidelines

Atram (Carvedilol) is administered via the oral route in the form of film-coated tablets. The instructions for its use are defined by a structured, step-wise approach based on the specific condition being managed. The core principle for use is a low-start, slow-titration regimen, where the dosage is gradually increased over time to reach the necessary maintenance level.


Administration and Timing

Principle Instruction
Dosing Frequency The tablet must be taken twice daily (BID) for all approved indications.
Timing with Meals The medicine must be taken with food to slow absorption and help mitigate certain effects.
Initial Dose Starting doses vary by condition: 3.125 mg twice daily for Chronic Heart Failure, or 6.25 mg twice daily for Hypertension.
Titration Schedule Dosage increases (doubling the dose) occur at predetermined intervals: generally every two weeks for Chronic Heart Failure or every one to two weeks for Hypertension, until the target dose is achieved.

Procedural Conditions

Therapy with Atram is intended for a long-term plan, and its administration requires specific handling protocols. Prior to initiation for Chronic Heart Failure, it is required that any existing fluid retention must be minimized. Crucially, the long-term use of this medicine must not be discontinued abruptly. If the regimen needs to stop, the dose must be systematically reduced over a period of one to two weeks, as gradual reduction is required. In the event of a missed dose, the patient should skip the dose if it is close to the next scheduled time and should never take a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Atram

Evidence for Use in Chronic Heart Failure

Research has explored the use of Atram in conditions marked by functional limitations, specifically chronic heart failure where the heart's pumping function is reduced. The research primarily involves large-scale, multi-center Randomized Controlled Trials (RCTs) and pooled analyses that combine data from several studies.

In these trials, researchers primarily monitored outcomes related to survival (all-cause mortality) and tracked hospitalizations related to cardiovascular causes. Studies also explored outcomes related to systemic or functional imbalance by monitoring objective measurements like the Left Ventricular Ejection Fraction (LVEF) and tracking patient-reported outcomes describing perceived discomfort or changes in activity level.

Evidence for Use Following a Heart Attack

Research also examined the use of Atram in adult patients who had recently survived a heart attack (myocardial infarction, or MI) and were identified as having reduced heart function afterward (low LVEF). This evidence was largely derived from one large trial that tracked patients for a defined period following the acute event.

In this research, studies monitored outcomes capturing physiological strain or stress, primarily focusing on tracking subsequent mortality events. Research also described the observations and measurements related to the degree of myocardial remodeling, an outcome related to heart chamber structure.

What is Still Uncertain About Atram

One key limitation is the absence of conclusive long-term outcomes data for all indications, as follow-up durations were limited in the primary controlled trials. Additionally, research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Evidence quality varies across studies, particularly in the pediatric population, where the primary trial did not achieve its main endpoint. Subgroup findings across different types of essential hypertension are also uncertain, as much of the evidence relies on broader class data.

Key Studies & References

  1. Carvedilol (Prescribing Information and Labeling)
  2. Effects of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
  3. Carvedilol (General Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Atram (FAQ)

Q: Can Atram be taken with over-the-counter pain relievers?

A: Official information regarding interactions focuses on specific prescription drug classes. However, general caution is sometimes noted when taking Atram with any over-the-counter medicines that may also lower blood pressure or heart rate, such as certain pain or cold preparations, as this could potentially lead to additive effects. Regulatory caution relates to understanding the ingredients of non-prescription medicines due to potential additive effects.

Q: Does Atram interact with herbal supplements?

A: Regulatory documents list interactions with certain agents that are known to significantly affect liver enzymes (CYP2D6 and CYP2C9). Official summaries do not list every herbal supplement available. Official guidance encourages awareness of whether a supplement is known to affect these liver enzymes, as this could potentially alter the concentration of Atram in the body.

Q: Can I drive or operate machinery while taking Atram?

A: Official product information notes that the ability to drive or operate complex machinery may be impaired by the use of Atram. This is due to common adverse reactions like dizziness and fatigue. This caution is considered especially relevant when treatment is initiated, after any dose increases, or if the medicine is taken alongside alcohol.

Q: What happens if I miss a scheduled dose of Atram?

A: Official guidance addresses the use of a missed dose by stating that it may be taken if remembered, provided it is not close to the next scheduled time. The official instructions strictly state that a double dose should never be taken to compensate for a missed one.

Q: Can I split or crush Atram tablets?

A: Atram is manufactured as film-coated tablets. The official prescribing information does not generally provide specific instructions for altering the physical form of the tablet, such as splitting or crushing. Concerns regarding administration or swallowing the tablet whole are typically reviewed with a healthcare provider for personalized guidance.

Q: Is Atram safe to use during pregnancy?

A: Official risk assessments indicate that use during pregnancy is permitted only if the potential benefit for the person outweighs the potential risk to the developing fetus, as human study data is limited. Regulatory documents also advise that if the medicine is used close to the time of birth, the newborn must be monitored for certain effects like low blood pressure and a slow heart rate.

Q: Is Atram safe to use while breastfeeding?

A: Regulatory documents state that Atram is known to be excreted into human milk. Due to the unknown effects this may have on the nursing infant, use of the medicine is generally not recommended for mothers who are breastfeeding.

Q: Does Atram interact with birth control pills?

A: Specific, major interactions between Atram and hormonal contraceptives (birth control pills) are not typically highlighted in official interaction summaries. The official label does not highlight this specific interaction, though potential drug effects causing severe stomach upset might reduce the effectiveness of oral contraceptives.

Q: Is Atram similar to other common medicines for the same condition?

A: Atram belongs to a group of medicines known as adrenergic blockers. According to official documents, it has a unique dual action mechanism. This means it functions as both a nonselective beta-blocker and an alpha-1 adrenergic blocker, which distinguishes its method of action from traditional beta-blockers.

Q: What are the most common reasons people stop taking Atram?

A: Official clinical trial and adverse reaction data indicate that the most common reasons patients may discontinue the medicine are typically related to adverse effects. These include the 'very common' reactions such as dizziness, fatigue, and hypotension (low blood pressure), or a slow heart rate that is severe enough to cause symptoms.

Q: Does Atram interact with alcohol?

A: Official safety precautions warn that alcohol may increase the blood pressure-lowering effects of Atram. This combination could increase the risk of side effects like dizziness or lightheadedness, particularly when treatment is initiated or following a dose adjustment.

Q: Can people with kidney problems use Atram?

A: Official product information states that no routine dose adjustment is necessary for patients with renal impairment (kidney problems). However, in heart failure patients with very low blood pressure, use of the medicine may lead to a reversible deterioration of kidney function. The need for careful monitoring is noted in patients with specific conditions.

Q: Are there any long-term health risks associated with Atram?

A: Atram is intended for chronic, long-term therapeutic use in its approved indications. For most individuals, the medicine is tolerated well over an extended period. Official information emphasizes that continuous use is generally associated with long-term patient monitoring.

Q: Is Atram approved in countries outside the US?

A: The active ingredient in Atram, Carvedilol, is approved and regulated for use in many countries outside the United States. This is evidenced by the existence of official regulatory documents issued by international bodies such as the European Medicines Agency (EMA) and the TGA in Australia.

Q: How is Atram eliminated from the body?

A: Regulatory documents describe how the medicine is processed in the body (pharmacokinetics). Atram is extensively metabolized, or broken down, primarily by the liver. The resulting breakdown products are mostly eliminated from the body through the bile and into the feces. Only a small percentage of the original dose is removed via the urine.

How should Atram be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define the mandatory storage and disposal instructions for Atram (Carvedilol tablets) to ensure stability and safety.

Storage Conditions:

Element Requirement
Temperature Store at 20 C to 25 C (68 F to 77 F). Do not store above 30 C.
Protection Must be protected from moisture and kept from freezing.
Packaging Dispense and store in a tight, light-resistant container.
Child Safety Mandatory to keep the product out of the sight and reach of children.

Disposal Instructions:

Unused or expired Atram must be safely thrown away. Patients should dispose of the product in accordance with local requirements. Unless specifically instructed, medicines should not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atram found in:

A-Z Index: